Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate

In this study, we describe two patients with Philadelphia chromosome-positive hematological malignancies who presented with secondary thrombotic microangiopathy that was most likely linked to the use of imatinib. Other potential causes of thrombotic microangiopathy were discarded, and the predisposing role of some comorbidities and potential short or long-term drug–drug interactions was assessed. The clinical and biological data were more indicative of atypical secondary hemolytic uremic syndrome in one of the cases and of secondary thrombotic microangiopathy with renal and cardiac impairment in the other, which is also categorized as secondary hemolytic uremic syndrome. The outcome was favorable after imatinib discontinuation and the treatment of severe cardiac and renal failures.

Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Ojeda-Uribe, M., Merieau, S., Guillon, M., Aujoulat, O., Hinschberger, O., Eisenmann, J.-C., Kenizou, D., Debliquis, A., Veyradier, A., Chantrel, F. Tags: Case Reports Source Type: research